Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Common cancer biomarkers.

Christopher F Basil1, Yingdong Zhao, Katia Zavaglia

  • 1Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Cancer Institute, NIH, Bethesda, Maryland 20892-1184, USA.

Cancer Research
|March 17, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Tumor Immunology Meets Oncology" (TIMO), 22 May-24 May 2025 in Brandenburg an der Havel, Germany.

Cancer immunology, immunotherapy : CII·2026
Same author

Inflammation and Colorectal Cancer Pathogenesis: Molecular, Immunological, and Environmental Features for Therapy Response and Resistances.

International journal of molecular sciences·2026
Same author

Interferon lambda in anti-viral defense and cancer: dual roles, mechanism and therapeutic potential.

Journal of translational medicine·2026
Same author

Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8<sup><b>+</b></sup> T cells.

Oncoimmunology·2026
Same author

Plasma GDF15 concentration predicts early recurrence after atrial arrhythmia ablation.

JCI insight·2026
Same author

Multiparametric staining - combined application of immunofluorescence and in-situ hybridization.

Methods in cell biology·2026

Researchers identified seven gene pairs as cancer biomarkers for improved cancer staging and early detection. These molecular markers show high accuracy in distinguishing malignant from benign tissues across various cancer types.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Conventional histopathology has limitations in cancer staging sensitivity and specificity.
  • Molecular tools offer potential for enhanced cancer diagnosis and prognosis.
  • There is a need for universal cancer markers applicable across diverse tumor types.

Purpose of the Study:

  • To identify cancer-specific molecular markers for detecting a broad range of cancer types.
  • To develop molecular tools that increase the sensitivity and specificity of cancer staging.
  • To find biomarkers overexpressed in malignant lesions, independent of tissue origin.

Main Methods:

  • Utilized 373 archival tissue samples (normal, benign, and malignant - colon, melanoma, ovarian, esophageal).

Related Experiment Videos

  • Employed a custom-made cDNA array platform for sample analysis.
  • Applied leave-one-out cross-validation and gene pairing analysis on training and prediction datasets.

    • Main Results:

    • Identified seven gene pairs with high predictive power (87%) in distinguishing malignant from benign lesions.
    • Achieved 94% accuracy in segregating malignant from benign tissues using receiver operator characteristic curves.
    • Discovered biomarkers ubiquitously expressed by cancers of distinct histology, a novel finding.

    Conclusions:

    • The identified gene pairs serve as robust, broadly applicable cancer biomarkers.
    • These biomarkers can enhance cancer staging accuracy and facilitate early detection of recurrence.
    • The discovered markers are selectively expressed in cancerous tissues, suggesting a link to oncogenesis.